Spots Global Cancer Trial Database for mesothelin
Every month we try and update this database with for mesothelin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intervention of CAR-T Against Cervical Cancer | NCT03356795 | Cervical Cancer | Cervical cancer... | 18 Years - 70 Years | Shenzhen Geno-Immune Medical Institute | |
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers | NCT06196294 | Pancreas Cancer Lung Cancer Liver Cancer Mesothelioma CAR-T Cell Ther... Solid Tumor, Ad... | Cell therapy fo... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies | NCT02485119 | Neoplasms | BAY94-9343 | 20 Years - | Bayer | |
| A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer | NCT00325494 | Pancreatic Canc... Mesothelioma Ovarian Cancer Non-Small Cell ... | MORAb-009 | 18 Years - | Morphotek | |
| Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors | NCT04981691 | Refractory Mali... | anti-MESO CAR T... | 18 Years - 80 Years | Ruijin Hospital | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | NCT03436732 | Mesothelioma | LMB-100 SEL-110 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | NCT02824042 | Medical Oncolog... | Anetumab ravtan... Itraconazole | 18 Years - | Bayer | |
| Antigen-specific T Cells Against Lung Cancer | NCT03356808 | Lung Cancer | Lung cancer-spe... | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors | NCT05410717 | Stage IV Ovaria... Testis Cancer, ... Endometrial Can... CAR NK | Claudin6, GPC3,... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Intervention of CAR-T Against Cervical Cancer | NCT03356795 | Cervical Cancer | Cervical cancer... | 18 Years - 70 Years | Shenzhen Geno-Immune Medical Institute | |
| Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | NCT02798536 | Mesothelioma | LMB-100 nab-paclitaxel | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | NCT05779917 | Pancreas Cancer CAR-T Cell Ther... Mesothelin Solid Tumor, Ad... | CAR-T cells | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin as a New Tumor Marker for Ovarian Cancer | NCT00155740 | Ovarian Cancer | 15 Years - 90 Years | National Taiwan University Hospital | ||
| A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies | NCT03926143 | Solid Tumors | BAY94-9343 (Ane... | 18 Years - | Bayer | |
| Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting | NCT02004262 | 2nd-line, 3rd-l... | GVAX Pancreas V... CRS-207 Chemotherapy cyclophosphamid... | 18 Years - | Aduro Biotech, Inc. | |
| Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | NCT02798536 | Mesothelioma | LMB-100 nab-paclitaxel | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin as a New Tumor Marker for Ovarian Cancer | NCT00155740 | Ovarian Cancer | 15 Years - 90 Years | National Taiwan University Hospital | ||
| Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment | NCT00585845 | Malignant Epith... Adenocarcinoma ... Carcinoma, Non-... Adenocarcinoma ... | CRS-207, Live-a... | 18 Years - | Anza Therapeutics, Inc. | |
| A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies | NCT03926143 | Solid Tumors | BAY94-9343 (Ane... | 18 Years - | Bayer | |
| Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | NCT03267173 | Pancreatic Canc... CAR | Chimeric antige... | 18 Years - 65 Years | First Affiliated Hospital of Harbin Medical University | |
| Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | NCT01675765 | Malignant Pleur... | Immunotherapy p... Immunotherapy w... | 18 Years - | Aduro Biotech, Inc. | |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers | NCT03198052 | Lung Cancer Cancer Immunotherapy CAR-T Cell | CAR-T cells tar... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation | NCT04203459 | Pancreatic Canc... Gut Microbiota CAR-T | 30 Years - 75 Years | First Affiliated Hospital of Harbin Medical University | ||
| Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | NCT02810418 | Neoplasms Pancreatic Neop... | LMB-100 Nab-Paclitaxel Mesothelin Expr... LMB-100 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer | NCT01417000 | Metastatic Panc... | GVAX Pancreas CRS-207 Cyclophosphamid... | 18 Years - | Aduro Biotech, Inc. | |
| The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients | NCT00173394 | Ovarian Cancer | 18 Years - 80 Years | National Taiwan University Hospital | ||
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| Mesothelin as a New Tumor Marker for Ovarian Cancer | NCT00155740 | Ovarian Cancer | 15 Years - 90 Years | National Taiwan University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
